The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Non-Hodgkin Lymphoma Therapeutics-Global Market Insights and Sales Trends 2024
Synopsis
The global Non-Hodgkin Lymphoma Therapeutics market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Non-Hodgkin Lymphoma Therapeutics in various end use industries. The expanding demands from the Clinical Research and Treatment, are propelling Non-Hodgkin Lymphoma Therapeutics market. Chemotherapy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Targeted Therapy segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Non-Hodgkin Lymphoma Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Non-Hodgkin Lymphoma Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Non-Hodgkin Lymphoma Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Non-Hodgkin Lymphoma Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Non-Hodgkin Lymphoma Therapeutics covered in this report include Bristol Myers Squibb, Celgene, Eli Lilly, F. Hoffman La-Roche, GlaxoSmithKline, Accredo Health Group, Baxter International, Bayer and Cephalon, etc.
The global Non-Hodgkin Lymphoma Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Bristol Myers Squibb
Celgene
Eli Lilly
F. Hoffman La-Roche
GlaxoSmithKline
Accredo Health Group
Baxter International
Bayer
Cephalon
Eisai Pharmaceuticals
Global Non-Hodgkin Lymphoma Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Non-Hodgkin Lymphoma Therapeutics market, Segment by Type:
Chemotherapy
Targeted Therapy
Global Non-Hodgkin Lymphoma Therapeutics market, by Application
Clinical Research
Treatment
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Non-Hodgkin Lymphoma Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
The global Non-Hodgkin Lymphoma Therapeutics market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Non-Hodgkin Lymphoma Therapeutics in various end use industries. The expanding demands from the Clinical Research and Treatment, are propelling Non-Hodgkin Lymphoma Therapeutics market. Chemotherapy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Targeted Therapy segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Non-Hodgkin Lymphoma Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Non-Hodgkin Lymphoma Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Non-Hodgkin Lymphoma Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Non-Hodgkin Lymphoma Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Non-Hodgkin Lymphoma Therapeutics covered in this report include Bristol Myers Squibb, Celgene, Eli Lilly, F. Hoffman La-Roche, GlaxoSmithKline, Accredo Health Group, Baxter International, Bayer and Cephalon, etc.
The global Non-Hodgkin Lymphoma Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Bristol Myers Squibb
Celgene
Eli Lilly
F. Hoffman La-Roche
GlaxoSmithKline
Accredo Health Group
Baxter International
Bayer
Cephalon
Eisai Pharmaceuticals
Global Non-Hodgkin Lymphoma Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Non-Hodgkin Lymphoma Therapeutics market, Segment by Type:
Chemotherapy
Targeted Therapy
Global Non-Hodgkin Lymphoma Therapeutics market, by Application
Clinical Research
Treatment
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Non-Hodgkin Lymphoma Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Non-Hodgkin Lymphoma Therapeutics
1.1 Non-Hodgkin Lymphoma Therapeutics Market Overview
1.1.1 Non-Hodgkin Lymphoma Therapeutics Product Scope
1.1.2 Non-Hodgkin Lymphoma Therapeutics Market Status and Outlook
1.2 Global Non-Hodgkin Lymphoma Therapeutics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Non-Hodgkin Lymphoma Therapeutics Market Size by Region (2018-2029)
1.4 Global Non-Hodgkin Lymphoma Therapeutics Historic Market Size by Region (2018-2023)
1.5 Global Non-Hodgkin Lymphoma Therapeutics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Non-Hodgkin Lymphoma Therapeutics Market Size (2018-2029)
1.6.1 North America Non-Hodgkin Lymphoma Therapeutics Market Size (2018-2029)
1.6.2 Europe Non-Hodgkin Lymphoma Therapeutics Market Size (2018-2029)
1.6.3 Asia-Pacific Non-Hodgkin Lymphoma Therapeutics Market Size (2018-2029)
1.6.4 Latin America Non-Hodgkin Lymphoma Therapeutics Market Size (2018-2029)
1.6.5 Middle East & Africa Non-Hodgkin Lymphoma Therapeutics Market Size (2018-2029)
2 Non-Hodgkin Lymphoma Therapeutics Market by Type
2.1 Introduction
2.1.1 Chemotherapy
2.1.2 Targeted Therapy
2.2 Global Non-Hodgkin Lymphoma Therapeutics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Non-Hodgkin Lymphoma Therapeutics Historic Market Size by Type (2018-2023)
2.2.2 Global Non-Hodgkin Lymphoma Therapeutics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Non-Hodgkin Lymphoma Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Non-Hodgkin Lymphoma Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Non-Hodgkin Lymphoma Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Non-Hodgkin Lymphoma Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Non-Hodgkin Lymphoma Therapeutics Revenue Breakdown by Type (2018-2029)
3 Non-Hodgkin Lymphoma Therapeutics Market Overview by Application
3.1 Introduction
3.1.1 Clinical Research
3.1.2 Treatment
3.2 Global Non-Hodgkin Lymphoma Therapeutics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Non-Hodgkin Lymphoma Therapeutics Historic Market Size by Application (2018-2023)
3.2.2 Global Non-Hodgkin Lymphoma Therapeutics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Non-Hodgkin Lymphoma Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Non-Hodgkin Lymphoma Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Non-Hodgkin Lymphoma Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Non-Hodgkin Lymphoma Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Non-Hodgkin Lymphoma Therapeutics Revenue Breakdown by Application (2018-2029)
4 Non-Hodgkin Lymphoma Therapeutics Competition Analysis by Players
4.1 Global Non-Hodgkin Lymphoma Therapeutics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Non-Hodgkin Lymphoma Therapeutics as of 2022)
4.3 Date of Key Players Enter into Non-Hodgkin Lymphoma Therapeutics Market
4.4 Global Top Players Non-Hodgkin Lymphoma Therapeutics Headquarters and Area Served
4.5 Key Players Non-Hodgkin Lymphoma Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 Non-Hodgkin Lymphoma Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Bristol Myers Squibb
5.1.1 Bristol Myers Squibb Profile
5.1.2 Bristol Myers Squibb Main Business
5.1.3 Bristol Myers Squibb Non-Hodgkin Lymphoma Therapeutics Products, Services and Solutions
5.1.4 Bristol Myers Squibb Non-Hodgkin Lymphoma Therapeutics Revenue (US$ Million) & (2018-2023)
5.1.5 Bristol Myers Squibb Recent Developments
5.2 Celgene
5.2.1 Celgene Profile
5.2.2 Celgene Main Business
5.2.3 Celgene Non-Hodgkin Lymphoma Therapeutics Products, Services and Solutions
5.2.4 Celgene Non-Hodgkin Lymphoma Therapeutics Revenue (US$ Million) & (2018-2023)
5.2.5 Celgene Recent Developments
5.3 Eli Lilly
5.3.1 Eli Lilly Profile
5.3.2 Eli Lilly Main Business
5.3.3 Eli Lilly Non-Hodgkin Lymphoma Therapeutics Products, Services and Solutions
5.3.4 Eli Lilly Non-Hodgkin Lymphoma Therapeutics Revenue (US$ Million) & (2018-2023)
5.3.5 F. Hoffman La-Roche Recent Developments
5.4 F. Hoffman La-Roche
5.4.1 F. Hoffman La-Roche Profile
5.4.2 F. Hoffman La-Roche Main Business
5.4.3 F. Hoffman La-Roche Non-Hodgkin Lymphoma Therapeutics Products, Services and Solutions
5.4.4 F. Hoffman La-Roche Non-Hodgkin Lymphoma Therapeutics Revenue (US$ Million) & (2018-2023)
5.4.5 F. Hoffman La-Roche Recent Developments
5.5 GlaxoSmithKline
5.5.1 GlaxoSmithKline Profile
5.5.2 GlaxoSmithKline Main Business
5.5.3 GlaxoSmithKline Non-Hodgkin Lymphoma Therapeutics Products, Services and Solutions
5.5.4 GlaxoSmithKline Non-Hodgkin Lymphoma Therapeutics Revenue (US$ Million) & (2018-2023)
5.5.5 GlaxoSmithKline Recent Developments
5.6 Accredo Health Group
5.6.1 Accredo Health Group Profile
5.6.2 Accredo Health Group Main Business
5.6.3 Accredo Health Group Non-Hodgkin Lymphoma Therapeutics Products, Services and Solutions
5.6.4 Accredo Health Group Non-Hodgkin Lymphoma Therapeutics Revenue (US$ Million) & (2018-2023)
5.6.5 Accredo Health Group Recent Developments
5.7 Baxter International
5.7.1 Baxter International Profile
5.7.2 Baxter International Main Business
5.7.3 Baxter International Non-Hodgkin Lymphoma Therapeutics Products, Services and Solutions
5.7.4 Baxter International Non-Hodgkin Lymphoma Therapeutics Revenue (US$ Million) & (2018-2023)
5.7.5 Baxter International Recent Developments
5.8 Bayer
5.8.1 Bayer Profile
5.8.2 Bayer Main Business
5.8.3 Bayer Non-Hodgkin Lymphoma Therapeutics Products, Services and Solutions
5.8.4 Bayer Non-Hodgkin Lymphoma Therapeutics Revenue (US$ Million) & (2018-2023)
5.8.5 Bayer Recent Developments
5.9 Cephalon
5.9.1 Cephalon Profile
5.9.2 Cephalon Main Business
5.9.3 Cephalon Non-Hodgkin Lymphoma Therapeutics Products, Services and Solutions
5.9.4 Cephalon Non-Hodgkin Lymphoma Therapeutics Revenue (US$ Million) & (2018-2023)
5.9.5 Cephalon Recent Developments
5.10 Eisai Pharmaceuticals
5.10.1 Eisai Pharmaceuticals Profile
5.10.2 Eisai Pharmaceuticals Main Business
5.10.3 Eisai Pharmaceuticals Non-Hodgkin Lymphoma Therapeutics Products, Services and Solutions
5.10.4 Eisai Pharmaceuticals Non-Hodgkin Lymphoma Therapeutics Revenue (US$ Million) & (2018-2023)
5.10.5 Eisai Pharmaceuticals Recent Developments
6 North America
6.1 North America Non-Hodgkin Lymphoma Therapeutics Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Non-Hodgkin Lymphoma Therapeutics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Non-Hodgkin Lymphoma Therapeutics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Non-Hodgkin Lymphoma Therapeutics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Non-Hodgkin Lymphoma Therapeutics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Non-Hodgkin Lymphoma Therapeutics Market Dynamics
11.1 Non-Hodgkin Lymphoma Therapeutics Industry Trends
11.2 Non-Hodgkin Lymphoma Therapeutics Market Drivers
11.3 Non-Hodgkin Lymphoma Therapeutics Market Challenges
11.4 Non-Hodgkin Lymphoma Therapeutics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
